Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.

For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as

Is Patent “Evergreening” Restricting Access to Medicine/Device Combination Products? Patent evergreening has emerged as a contentious issue in the pharmaceutical

Healthcare systems including hospitals are taking care-related and business-related steps to cope with rapidly increasing drug prices.

The pharmaceutical industry stands at a critical crossroads where innovative pricing strategies are becoming essential to balance drug accessibility with